{
"id":"mk19_bb_en_s3",
"subspecialtyId":"en",
"title":"Diabetes Care for Hospitalized Patients",
"jsonContent":{
"type":"section",
"id":"mk19_bb_en_s3",
"title":{
"__html":"Diabetes Care for Hospitalized Patients"
},
"titleNode":{
"type":"section-title",
"hlId":"288478",
"children":[
"Diabetes Care for Hospitalized Patients"
]
},
"children":[
{
"type":"section",
"id":"mk19_bb_en_s3_1",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"2693b4",
"children":[
"Insulin is the preferred treatment for achieving inpatient glycemic control. Critically ill patients with type 2 diabetes are treated with IV insulin infusion when plasma glucose levels exceed 180 to 200 mg/dL. Glucose goals are 140 to 180 mg/dL."
]
},
{
"type":"p",
"hlId":"f9490d",
"children":[
"For nonâ€“critically ill patients who are eating, the insulin regimen should incorporate both basal and prandial coverage. Prandial coverage can be supplemented with correction factor insulin for preprandial hyperglycemia."
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"50535d",
"children":[
"Do not select sliding scale insulin alone to treat in-hospital hyperglycemia."
]
},
" ",
{
"type":"list-item",
"hlId":"107199",
"children":[
" ",
{
"type":"alert",
"children":[
"Tight inpatient glycemic control (80-110 mg/dL [4.4-6.1 mmol/L]) is not consistently associated with improved outcomes and may increase mortality."
]
},
" "
]
},
" "
]
},
{
"type":"p",
"hlId":"be696c",
"children":[
"Continuing outpatient oral or noninsulin injectable agents is not recommended when patients are hospitalized because of the potential for hemodynamic or nutritional changes. Continuing oral agents should be considered only in a stable inpatient with glycemic control at goal who has no anticipated changes in nutrition or hemodynamic status."
]
}
]
}
]
},
"tablesContent":{
}
}